Develops targeted radiopharmaceutical therapies, specifically radioantibodies like CONV01-α, that bind to prostate-specific membrane antigen (PSMA) to deliver localized radiation to prostate cancer cells. This approach aims to improve treatment efficacy and patient outcomes by precisely targeting cancerous tissues while minimizing damage to surrounding healthy cells.
Funding
$130M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer therapies often lack precision, leading to damage of healthy tissues surrounding the tumor and resulting in significant side effects for patients. Systemic radiation treatments can expose the entire body to radiation, limiting the dosage that can be safely administered to the tumor site.
Solution
Convergent Therapeutics is developing targeted radiopharmaceutical therapies using radioantibodies to selectively deliver radiation directly to cancer cells. Their lead candidate, CONV01-α, is a radioantibody that binds to prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. By targeting PSMA, CONV01-α delivers a localized dose of alpha radiation to the tumor microenvironment, minimizing damage to surrounding healthy tissues. This approach aims to improve treatment efficacy and reduce systemic toxicity, potentially leading to better outcomes for cancer patients. The company's technology seeks to unlock the full potential of alpha radioantibodies, offering a more precise and powerful approach to cancer treatment.
Target Audience
The primary target audience includes oncologists and patients with cancers that express specific, targetable markers, with an initial focus on prostate cancer.
Features
- Utilizes radioantibodies to target specific cancer cell markers, such as PSMA in prostate cancer
- Employs alpha-emitting payloads for potent and localized radiation delivery
- Designed to minimize radiation exposure to healthy neighboring cells and tissues
- CONV01-α is the lead radioantibody candidate